Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Padam S, Tang A, Martinez N, Schmolze D, Presant C, Ebrahimi B, Yeon C, Sedrak M, Patel N, Portnow J, Lee P, Mortimer J. Yuan Y, et al. Among authors: schmolze d. Eur J Cancer. 2021 Sep;154:11-20. doi: 10.1016/j.ejca.2021.05.035. Epub 2021 Jul 1. Eur J Cancer. 2021. PMID: 34217908 Free PMC article. Clinical Trial.
Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.
Hsu PY, Wu VS, Kanaya N, Petrossian K, Hsu HK, Nguyen D, Schmolze D, Kai M, Liu CY, Lu H, Chu P, Vito CA, Kruper L, Mortimer J, Chen S. Hsu PY, et al. Among authors: schmolze d. Clin Cancer Res. 2018 Jan 15;24(2):395-406. doi: 10.1158/1078-0432.CCR-17-1983. Epub 2017 Oct 27. Clin Cancer Res. 2018. PMID: 29079660 Free PMC article.
Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
Yuan Y, Kos FJ, He TF, Yin HH, Li M, Hardwick N, Zurcher K, Schmolze D, Lee P, Pillai RK, Chung V, Diamond DJ. Yuan Y, et al. Among authors: schmolze d. Oncoimmunology. 2017 Aug 11;6(12):e1363138. doi: 10.1080/2162402X.2017.1363138. eCollection 2017. Oncoimmunology. 2017. PMID: 29209571 Free PMC article.
Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.
Afkhami M, Schmolze D, Yost SE, Frankel PH, Dagis A, Amanam IU, Telatar M, Nguyen K, Yu KW, Luu T, Pillai R, Aoun PA, Mortimer J, Yuan Y. Afkhami M, et al. Among authors: schmolze d. PLoS One. 2019 Nov 6;14(11):e0224726. doi: 10.1371/journal.pone.0224726. eCollection 2019. PLoS One. 2019. PMID: 31693690 Free PMC article.
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, Pillai R, Robinson K, Tang A, Martinez N, Portnow J, Wen W, Yim JH, Brauer HA, Ren Y, Luu T, Mortimer J, Yuan Y. Lee JS, et al. Among authors: schmolze d. Breast Cancer Res. 2019 Nov 8;21(1):119. doi: 10.1186/s13058-019-1202-4. Breast Cancer Res. 2019. PMID: 31703728 Free PMC article. Clinical Trial.
Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis.
He TF, Yost SE, Frankel PH, Dagis A, Cao Y, Wang R, Rosario A, Tu TY, Solomon S, Schmolze D, Mortimer J, Lee P, Yuan Y. He TF, et al. Among authors: schmolze d. PLoS One. 2020 Mar 9;15(3):e0229955. doi: 10.1371/journal.pone.0229955. eCollection 2020. PLoS One. 2020. PMID: 32150594 Free PMC article.
57 results